Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug 14;232(2):346-358.
doi: 10.1093/infdis/jiaf270.

Plasma Lipid Metabolites Differentiate Metabolic From Viral Chronic Liver Disease

Kara Wegermann  1 , Joseph E Lucas  2 , Laura Dubois  3 , Rebecca Mangus  4 , Zhong Li  3 , Cynthia A Moylan  1   5 , Keyur Patel  6 , Susanna Naggie  4   5
Affiliations

Plasma Lipid Metabolites Differentiate Metabolic From Viral Chronic Liver Disease

Kara Wegermann et al. J Infect Dis. .

Abstract

Background: Lipid metabolism is altered in human immunodeficiency virus (HIV) infection and chronic liver diseases, but common and unique pathways have not been elucidated, limiting prevention and treatment strategies. The aim of this study was to discover lipid metabolite signatures for persons with HIV (PWH), PWH with HCV coinfection (PWH-HCV), and individuals with metabolic dysfunction-associated steatotic liver disease and steatohepatitis (MASLD, MASH).

Methods: Plasma metabolite profiling was performed in adult participants in 5 cohorts from a single center: PWH (n = 50), PWH-HCV (n = 50), HIV-negative biopsy-proven MASLD (n = 46), and MASH (n = 50), and controls without HIV or chronic liver disease (n = 29). Plasma metabolites were assessed using Biocrates Q500, bile acid, and oxylipin assays. Latent factor analysis along with unadjusted and adjusted logistic regression models were performed. Significance was defined as P value < .05 and false discovery rate < 0.10.

Results: Compared to controls, 457 of 816 measured metabolites were detected at different levels in PWH, 352 in PWH-HCV, 466 in MASLD, and 487 in MASH. Triglycerides and oxylipins were increased across disease states, but to a higher degree in PWH. PWH-HCV had a distinct metabolite signature with decreased ceramides and sphingomyelins. Levels of bile acid, amino acid, and fatty acid metabolites also differentiated cohorts.

Conclusions: Lipid metabolites demonstrated pathways common to, and unique to, HIV, HCV, and MASLD. Further studies will hopefully reveal the pathogenic role of these metabolites in liver disease severity, particularly in PWH with steatotic liver disease.

Keywords: HIV; MASLD; biomarker; metabolite; steatosis.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. The authors do not have any conflicts of interest relevant to this manuscript.

References

    1. Smith CJ, Ryom L, Weber R, et al. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet 2014; 384:241–8. - PubMed
    1. Platt L, Easterbrook P, Gower E, et al. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. Lancet Infect Dis 2016; 16:797–808. - PubMed
    1. Riebensahm C, Berzigotti A, Surial B, et al. Factors associated with liver steatosis in people with human immunodeficiency virus on contemporary antiretroviral therapy. Open Forum Infect Dis 2022; 9:ofac538. - PMC - PubMed
    1. Toribio M, Park MH, Zanni MV, et al. HDL cholesterol efflux capacity in newly diagnosed HIV and effects of antiretroviral therapy. J Clin Endocrinol Metab 2017; 102:4250–9. - PMC - PubMed
    1. Koutkia P, Grinspoon S. HIV-associated lipodystrophy: pathogenesis, prognosis, treatment, and controversies. Annu Rev Med 2004; 55:303–17. - PubMed